Rebecca Shatsky: RSClin tool is still really underutilized by oncologists

Rebecca Shatsky shared on X:

“RSClin tool is still really underutilized by oncologists to evaluate individual risk of chemotherapy benefit and late distant relapse!

‘Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival’ | NEJM Evidence.

Authors:  Joseph A. Sparano, Michael Crager, Robert J. Gray, Gong Tang, Jess Hoag, Frederick L. Baehner, Steven Shak, Della F. Makower, Kathy S. Albain,Daniel F. Hayes, Charles E. Geyer, Jr., Elizabeth C. Dees, Matthew P. Goetz, John A. Olson, Jr.,  Tracy Lively,  Sunil S. Badve, Thomas J. Saphner, Timothy J. Whelan, Virginia G. Kaklamani,Norman Wolmark, George W. Sledge, Jr., and Salomon M. Stemmer.”

Source: Rebecca Shatsky/X

Rebecca Shatsky is an Associate Professor at UC San Diego Health, Breast Medical Oncology Co-Team Leader, Scientific Director of the Inflammatory and Triple Negative Breast Cancer Program. She is a member of the NCCN guideline panel for Genetic/High-Risk Assessment of Breast, Ovarian and Pancreatic Cancer and the panel for the treatment of Cancer-Associated Pain.

Her work has been published in JAMA Oncology, Cancer Cell and Molecular Cancer Therapeutics, among others. Dr. Shatsky is a member of the American Association for Cancer Research and the American Society of Clinical Oncology.